Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and refreshing, despite the challenging developments outside your window. Nonetheless, the world keeps spinning, so we are busy reviewing our to-do list and readying ourselves for another busy day. To cope, we have fired up the coffee kettle and are brewing a cup of stimulation — salted caramel mocha is the choice today — and invite you to join us. Meanwhile, here are some tidbits. Hope your day goes well, and do stay in touch. …

Merck (MRK) will stop developing both formulations of the Covid-19 vaccines the company was working on, citing inadequate immune responses to the shots, STAT writes. The company had adopted a different strategy from rivals by using a more traditional approach of focusing on shots based on weakened viruses. Work will continue on at least one of the vaccines, which is being developed in partnership with the International AIDS Vaccine Initiative, to see if using a different route of administration would improve effectiveness.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.